GFR

ILUS Finalizes Acquisition and Provides Shareholder Update

Retrieved on: 
Vendredi, octobre 6, 2023
OTC, Mergers and acquisitions, Acquisition, Kodak, Registration statement, Replay Solutions, JP, File, Public security, NYSE American, Growth, BHP, GFR, News, Register, ERT, Security (finance), Management, Holding company

ILUS’ Industrial subsidiary, Quality Industrial Corp. (QIND), successfully filed its S-1 Registration Statement on the 19th of September, 2023.

Key Points: 
  • ILUS’ Industrial subsidiary, Quality Industrial Corp. (QIND), successfully filed its S-1 Registration Statement on the 19th of September, 2023.
  • We now look forward to announcing our next strategic acquisition and exhibiting results of the progress made in our businesses,” added ILUS CEO, Nicolas Link.
  • During the third quarter, ILUS finalized the strategy and administrative procedures to spin out several of its public safety businesses into Emergency Response Technologies (ERT), which is wholly owned by ILUS.
  • ILUS wishes to inform Shareholders that its next Annual Shareholder Meeting will take place in Miami on Friday the 26th of January, 2024.

EQS-News: New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients

Retrieved on: 
Mardi, octobre 17, 2023
EGFR, Mayo Clinic, Physician, Acute kidney injury, Radboud University Nijmegen, AKI, Kidney, Gold, Round Table, Creatinine, Radboud University Medical Center, Diagnosis, Intensive care medicine, Chronic kidney disease, Research, GFR, Patient, Medical imaging, Medical device

PenKid is a kidney function biomarker that correlates with gold standard GFR measurements in stable and acute kidney injury (AKI) patients.

Key Points: 
  • PenKid is a kidney function biomarker that correlates with gold standard GFR measurements in stable and acute kidney injury (AKI) patients.
  • Based on penKid, a new formula was developed to estimate the GFR, outperforming widely used conventional equations based on creatinine alone.
  • Hennigsdorf/Berlin, Germany, October 5, 2023 - Diagnostic company SphingoTec GmbH (“SphingoTec”) announces that a new, improved formula has been developed for estimating the GFR using its kidney function biomarker penKid (1).
  • According to the data, penKid strongly correlates with the measured GFR (mGFR), while the penKid-based formula for estimating GFR performs better than routinely used equations.

DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease

Retrieved on: 
Jeudi, octobre 12, 2023
Cardiovascular disease, SELECT, Urine, Novo Nordisk, Death, Research, Risk, CKD, IA Financial Group, Mortality, SGLT2, Health, Type 2, FLOW, Type 2 diabetes, Kidney, Proteinuria, Chronic kidney disease, Clinical trial, DaVita Inc., Patient, C-peptide, GFR, News, Kidney disease, ACE, Pharmaceutical industry, Medical imaging

The following statement can be attributed to Dr. Jeff Giullian, chief medical officer for DaVita Inc.

Key Points: 
  • The following statement can be attributed to Dr. Jeff Giullian, chief medical officer for DaVita Inc.
    "We've been closely monitoring the developments related to GLP-1s, and are excited about the potential benefits this class of drugs could have on society and patients with kidney disease.
  • We will continue monitoring closely as further evidence becomes available to identify the potential benefit of GLP-1s to those afflicted with kidney disease.
  • In the meantime, DaVita remains focused on providing exceptional patient care and advancing the practice of kidney care."
  • The trial sought to demonstrate benefits for the composite endpoint comprised of five separate endpoints: death from kidney disease; death from cardiovascular disease; sustained reduction in GFR by at least 50%; progression to stage 5 CKD; and initiation of chronic kidney replacement therapy.

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Retrieved on: 
Mercredi, septembre 27, 2023
Kidney disease, ESRD, US Foods, IR, Chronic kidney disease, PBC, ODD, Cochlea, SCCHN, Head, Alport syndrome, Neck, Trial of the century, Hypertension, Proteinuria, Internet, Primary biliary cholangitis, Sustainability, Genetic disorder, Patient, Huber loss, CALT, FDA, SA, IPF, CKD, Gene, Idiopathic pulmonary fibrosis, Food, Pharmaceutical industry, Satellite navigation device, GFR, Alport

STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.

Key Points: 
  • STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.
  • Based on supportive pre-clinical work, Calliditas plans to initiate a randomized, placebo-controlled phase 2 clinical study in Alport syndrome with around 20 patients in the fourth quarter of 2023.
  • "We are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander.
  • Alport syndrome is a genetic disorder arising from the mutations in the genes that code for type 4 collagen.

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Retrieved on: 
Mercredi, septembre 27, 2023
Kidney disease, ESRD, US Foods, IR, Chronic kidney disease, PBC, ODD, Cochlea, SCCHN, Head, Alport syndrome, Neck, Trial of the century, Hypertension, Proteinuria, Internet, Primary biliary cholangitis, Sustainability, Genetic disorder, Patient, Huber loss, CALT, FDA, SA, IPF, CKD, Gene, Idiopathic pulmonary fibrosis, Food, Pharmaceutical industry, Satellite navigation device, GFR, Alport

STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.

Key Points: 
  • STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.
  • Based on supportive pre-clinical work, Calliditas plans to initiate a randomized, placebo-controlled phase 2 clinical study in Alport syndrome with around 20 patients in the fourth quarter of 2023.
  • "We are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander.
  • Alport syndrome is a genetic disorder arising from the mutations in the genes that code for type 4 collagen.

Arkstone Medical Solutions Launches Breakthrough OneChoice Report for Microbiology Lab Results

Retrieved on: 
Jeudi, août 24, 2023
GFR, Allergy, Communication, Infection, BOCA, Intelligence, Kidney disease, Patient, Entrepreneurship, Translation, Pathfinder, Health, Microbiology, Pharmaceutical industry

BOCA RATON, Fla., Aug. 24, 2023 /PRNewswire/ -- Arkstone Medical Solutions, a trailblazer in laboratory infectious disease reporting and proactive antimicrobial stewardship, has unveiled its latest innovation—the OneChoice report for microbiology lab results. Building on the success of its molecular lab results OneChoice report, which has already benefited hundreds of thousands of patients and is trusted by thousands of healthcare providers, Arkstone now extends its revolutionary technology to the wider realm of microbiology. 

Key Points: 
  • BOCA RATON, Fla., Aug. 24, 2023 /PRNewswire/ -- Arkstone Medical Solutions, a trailblazer in laboratory infectious disease reporting and proactive antimicrobial stewardship, has unveiled its latest innovation—the OneChoice report for microbiology lab results.
  • Building on the success of its molecular lab results OneChoice report, which has already benefited hundreds of thousands of patients and is trusted by thousands of healthcare providers, Arkstone now extends its revolutionary technology to the wider realm of microbiology.
  • "With the launch of the OneChoice report for microbiology lab results, Arkstone is poised to make an even greater impact on the healthcare landscape," said Dave Gross, Co-Founder & CTO of Arkstone.
  • The OneChoice report for microbiology lab results solidifies Arkstone's role as the leading provider of laboratory infectious disease reporting and proactive antimicrobial stewardship.

Crowley, GFR Media Carry Roberto Clemente's Legacy Forward

Retrieved on: 
Vendredi, août 18, 2023
GFR, New York Yankees, Partnership, Life, Season, Washington Nationals, PNC Park, Athlete, Piracy, Pittsburgh Pirates, MVP, Transport, Family, Film industry, Airline, El Nuevo Día

JACKSONVILLE, Fla., Aug. 18, 2023 /PRNewswire-PRWeb/ -- Longtime Puerto Rico shipping and logistics company Crowley has partnered with El Nuevo Día to amplify the legacy of Roberto Clemente Walker— from San Juan to Pittsburgh and beyond. This comes as the Pittsburgh Pirates and Clemente family prepare to welcome "3,000," a photographic exhibit dedicated to honoring the Hall-of-Famer, humanitarian, and beloved Puerto Rican hometown hero.

Key Points: 
  • JACKSONVILLE, Fla., Aug. 18, 2023 /PRNewswire-PRWeb/ -- Longtime Puerto Rico shipping and logistics company Crowley has partnered with El Nuevo Día to amplify the legacy of Roberto Clemente Walker— from San Juan to Pittsburgh and beyond.
  • "As Puerto Rico's longest serving U.S. shipping and logistics company, we are grateful to carry forward the humanitarian legacy of a beloved national hero by delivering the '3,000' exhibit from Puerto Rico to Pittsburgh," said Sal Menoyo, vice president of Puerto Rico and Caribbean logistics, Crowley.
  • I am certain that Pittsburgh will welcome '3,000' with the same sense of pride as they would celebrating one of the city's hometown heroes," said Pedro Zorrilla, CEO of GFR Media.
  • On behalf of my family, we are grateful to GFR and El Nuevo Día, for documenting his life and the milestone 3,000th hit so beautifully while shining a light on his legacy," said Luis Roberto Clemente, son of the late Roberto and Vera Clemente and director of the Roberto Clemente Foundation Legacy Program.

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

Retrieved on: 
Mardi, août 8, 2023
Health, FDA, Radiology, Research, Science, Pharmaceutical, Biotechnology, GFR, Pregnancy, Central nervous system, Gadobutrol, Fresenius (company), Diabetes, NSF, CAD, History, Glomerular filtration rate, Brain, USP, Hypertension, Contraindication, Incidence, Acute kidney injury, MRI, Hospital, Magnetic resonance imaging, Dizziness, Patient, Risk, Nephrogenic systemic fibrosis, Nausea, Coronary artery disease, Headache, Anaphylaxis, Rest, Death, Gadolinium, Medical imaging, Pharmaceutical industry, Birth control, Vaccine

Fresenius Kabi Gadobutrol Injection, a high-relaxivity macrocyclic agent, is available immediately in the United States.

Key Points: 
  • Fresenius Kabi Gadobutrol Injection, a high-relaxivity macrocyclic agent, is available immediately in the United States.
  • It is the second MRI offering in the company’s growing radiology portfolio , which also includes:
    "Fresenius Kabi is pleased to introduce Gadobutrol Injection as the newest addition to our U.S. radiology portfolio, expanding the range of cost-effective contrast agent options available to hospitals and clinics," said John Ducker, president and CEO of Fresenius Kabi USA.
  • Gadobutrol Injection is a gadolinium-based contrast agent indicated for use with MRI.1 It is the fourth product offering in the Fresenius Kabi radiology portfolio, which first launched in July 2022 with the introduction of Iodixanol Injection, USP during a nationwide shortage.
  • Fresenius Kabi Gadobutrol Injection is preservative-free, and the container closure is not made with natural rubber latex.

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

Retrieved on: 
Vendredi, juillet 7, 2023
Glycated hemoglobin, GFR, LSE, Obesity, American Diabetes Association, Chronic kidney disease, Diabetes, Type 2 diabetes, EGFR, SALT, Patient, Risk, RWE, DKD, Diabetic nephropathy, ADA, CKD, Kidney disease, Disease, Pharmaceutical industry

LONDON and SALT LAKE CITY, July 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced late-breaking new clinical data demonstrating that KidneyIntelX in vitro prognostic use was associated with post-test actions that led to sustained improvements in both type 2 diabetes and chronic kidney disease health through 12 months. The results are from the evaluation of 2,317 patients being followed in a large real-world evidence (RWE) study in New York City. The twelve-month outcome data were presented at the American Diabetes Association (ADA) 83rd Scientific Sessions held June 23-26, 2023, in San Diego, California.

Key Points: 
  • The results are from the evaluation of 2,317 patients being followed in a large real-world evidence (RWE) study in New York City.
  • The twelve-month outcome data were presented at the American Diabetes Association (ADA) 83rd Scientific Sessions held June 23-26, 2023, in San Diego, California.
  • In addition, during the ADA meetings, the Company presented validation data from a new IVD assay developed utilizing the KidneyIntelX platform.
  • Commenting on the data releases at the American Diabetes Association 83rd Scientific Sessions, Dr. Michael Donovan, Chief Medical Officer at Renalytix adds, “We are at an important inflection point in the overall understanding and management of kidney disease progression in the type 2 diabetic patient population.

MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

Retrieved on: 
Mercredi, juin 21, 2023
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, GFR, Hyperkalemia, Carcinoma, Radiation, Nephrotoxicity, Biodistribution, Blood urea nitrogen, Dosimetry, Half-life, Creatinine, Overalls, Quality of life, Glomerular filtration rate, NET, Dicarboxylic acid, Vomiting, Serum albumin, MD, Patient, Cancer, Kidney, Creatine, Nausea, BUN, PRRT, Phosphorus, Dietary supplement, Safety

Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.
  • A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia.
  • EBTATE administration appears to be safe without amino acid infusion.”
    Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs.
  • Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion.